Abstract
Alkylating drugs (ADs) belonging to the nitrogen mustard family are commonly used as cytostatic and immunosuppressive agents. Our previous in vitro studies demonstrated that in the case of gradual dose decrease, the number of targets for alkylation in the cell is also reduced and the drug switches from brutal cytostatic to cell growth modifier. At doses of 0.3 microg/ml and lower, the effects of ADs are no longer associated with DNA damage or stress/MAPK pathways activation. Instead, the disruption of signal transduction by the IL-2beta and/or TNFalpha cell surface receptors is observed. As a result, ADs in the doses 100-fold lower than cytostatic ones are capable to modify lymphocyte activity including the activity of regulatory T cells. We hypothesized that ADs may have a beneficial effect in the treatment of inflammatory diseases. Indeed, the application of non-cytotoxic doses of an AD melphalan reduces the severity of murine experimental colitis. Daily administration of melphalan (25 microg/kg body weight) markedly reduced the severity of DSS-colitis as determined by clinical and histological criteria. Moreover, the beneficial effect of melphalan was also shown in asthmatic patients. In 60% of these patients histological an...Continue Reading
References
Jul 1, 1976·Nature·A MitsuokaS Morikawa
Mar 1, 1975·The Journal of Experimental Medicine·P W AskenaseR K Gershon
Jan 1, 1990·Cancer Immunology, Immunotherapy : CII·S K HooverH D Bear
Oct 1, 1989·Seminars in Oncology·D C DollJ W Yarbro
Mar 1, 1988·European Journal of Immunology·R Yasunami, J F Bach
Apr 1, 1982·The Journal of Experimental Medicine·R J North
Jul 22, 1998·The Journal of Experimental Medicine·A M Thornton, E M Shevach
Aug 26, 1998·The Journal of Clinical Investigation·M ComabellaS J Khoury
Jan 7, 1999·The European Respiratory Journal·M KolbM Schmidt
Dec 28, 1999·Molecular and Cellular Biology·A KolbusP Angel
Jun 22, 2000·International Journal of Cancer. Journal International Du Cancer·M P VierboomC J Melief
Apr 5, 2001·Pharmacology·A L Pukhalsky, G V Shmarina
Jan 29, 2002·Nature Immunology·Jun ShimizuShimon Sakaguchi
Aug 28, 2002·Immunity·Thomas R MalekLin Kong
Jan 11, 2003·Science·Shohei HoriShimon Sakaguchi
Feb 14, 2003·Gut·A StallmachM Zeitz
Mar 4, 2003·Nature Immunology·Jason D FontenotAlexander Y Rudensky
Aug 28, 2004·Diabetes·Michael MatosChristophe Benoist
Sep 3, 2004·Nature Reviews. Immunology·Thomas R Malek, Allison L Bayer
Jan 1, 1995·Mediators of Inflammation·A PukhalskyS Khaidukov